#CRPSNeridronate

Neridronate has also been evaluated as a treatment for CRPS-I in a recent large multicentre, randomized, double-blind, placebo-controlled trial. About 82 patients with CRPS-I in either their hand or foot were randomly assigned to receive either an intravenous infusion of 100 mg of neridronate every 3 days for a total of 4 times or the placebo. After 50 days of the last infusion, the placebo group was treated with the same regimen of neridronate. In the double-blind phase, the visual analog scale (VAS) for pain was significantly lower in the neridronate-treated group after 20 days of treatment than in the placebo group and only continued to decrease for the next 20 days in the neridronate group. Oedema, pain induced by passive motion, allodynia, and hyperalgesia were significantly reduced in patients who were treated with neridronate compared with those in patients in the placebo group, and various functional indexes were increased. All neridronate-treated patients and only 45% of the patients who were treated with the placebo discontinued the symptomatic drugs within 2 weeks. The results obtained from patients had previously received the placebo, were subsequently treated with neridronate during the open-extension phase, and were similar to obtained from the neridronate-treated group during the blind phase, as represented by significant reductions in the VAS, oedema, and pain on passive motion; the disappearance of allodynia and hyperalgesia; and an improvement in functional scores after 40 days of follow-up. A complete normalization of the abnormal uptake was reported in patients undergoing bone scintigraphy, and a disappearance of localized bone oedema was observed on MRIs from 12 treated patients.

Read Full Article